Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19

PHASE1CompletedINTERVENTIONAL

Enrollment

175

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

June 25, 2021

Study Completion Date

November 30, 2021

Conditions

SARS-CoV Infection

Interventions

BIOLOGICAL

BBV154 Vaccine

Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10\^10 Virus Particle.

BIOLOGICAL

Placebo

Trial Locations (4)

AIIMS,Patna, Patna

Apollo Hospitals,Chennai, Chennai

St.Theresa Hospital, Hyderabad, Hyderabad

Gillurkar Multispeciality Hospital,Nagpur, Nagpur

All Listed Sponsors

lead

Bharat Biotech International Limited

INDUSTRY

NCT04751682 - Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19 | Biotech Hunter | Biotech Hunter